tetano
Editor, Senior Moderator
Virol J
. 2023 Feb 8;20(1):23.
doi: 10.1186/s12985-023-01973-9.
An overview on the treatments and prevention against COVID-19
Yunes Panahi[SUP] #[/SUP][SUP] 1 [/SUP], Armita Mahdavi Gorabi[SUP] 2 [/SUP], Sona Talaei[SUP] #[/SUP][SUP] 3 [/SUP], Fatemeh Beiraghdar[SUP] 4 [/SUP], Abolfazl Akbarzadeh[SUP] 5 [/SUP], Vahideh Tarhriz[SUP] 6 [/SUP], Hassan Mellatyar[SUP] 7 [/SUP]
Affiliations
Abstract
Background: The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to plague the world. While COVID-19 is asymptomatic in most individuals, it can cause symptoms like pneumonia, ARDS (acute respiratory distress syndrome), and death in others. Although humans are currently being vaccinated with several COVID-19 candidate vaccines in many countries, however, the world still is relying on hygiene measures, social distancing, and approved drugs.
Result: There are many potential therapeutic agents to pharmacologically fight COVID-19: antiviral molecules, recombinant soluble angiotensin-converting enzyme 2 (ACE2), monoclonal antibodies, vaccines, corticosteroids, interferon therapies, and herbal agents. By an understanding of the SARS-CoV-2 structure and its infection mechanisms, several vaccine candidates are under development and some are currently in various phases of clinical trials.
Conclusion: This review describes potential therapeutic agents, including antiviral agents, biologic agents, anti-inflammatory agents, and herbal agents in the treatment of COVID-19 patients. In addition to reviewing the vaccine candidates that entered phases 4, 3, and 2/3 clinical trials, this review also discusses the various platforms that are used to develop the vaccine COVID-19.
Keywords: Anti-inflammatory agents; Antiviral agents; Biologic agents; COVID-19; Coronaviruses; Herbal agents; SARS-CoV-2; Vaccine.
. 2023 Feb 8;20(1):23.
doi: 10.1186/s12985-023-01973-9.
An overview on the treatments and prevention against COVID-19
Yunes Panahi[SUP] #[/SUP][SUP] 1 [/SUP], Armita Mahdavi Gorabi[SUP] 2 [/SUP], Sona Talaei[SUP] #[/SUP][SUP] 3 [/SUP], Fatemeh Beiraghdar[SUP] 4 [/SUP], Abolfazl Akbarzadeh[SUP] 5 [/SUP], Vahideh Tarhriz[SUP] 6 [/SUP], Hassan Mellatyar[SUP] 7 [/SUP]
Affiliations
- PMID: 36755327
- DOI: 10.1186/s12985-023-01973-9
Abstract
Background: The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to plague the world. While COVID-19 is asymptomatic in most individuals, it can cause symptoms like pneumonia, ARDS (acute respiratory distress syndrome), and death in others. Although humans are currently being vaccinated with several COVID-19 candidate vaccines in many countries, however, the world still is relying on hygiene measures, social distancing, and approved drugs.
Result: There are many potential therapeutic agents to pharmacologically fight COVID-19: antiviral molecules, recombinant soluble angiotensin-converting enzyme 2 (ACE2), monoclonal antibodies, vaccines, corticosteroids, interferon therapies, and herbal agents. By an understanding of the SARS-CoV-2 structure and its infection mechanisms, several vaccine candidates are under development and some are currently in various phases of clinical trials.
Conclusion: This review describes potential therapeutic agents, including antiviral agents, biologic agents, anti-inflammatory agents, and herbal agents in the treatment of COVID-19 patients. In addition to reviewing the vaccine candidates that entered phases 4, 3, and 2/3 clinical trials, this review also discusses the various platforms that are used to develop the vaccine COVID-19.
Keywords: Anti-inflammatory agents; Antiviral agents; Biologic agents; COVID-19; Coronaviruses; Herbal agents; SARS-CoV-2; Vaccine.